

We Claim:

~~1. A compound which is crystalline ((R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol.~~

~~21. The compound according to claim 1 which is e~~Crystalline ((R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol monohydrate.

~~32. The compound according to claim 1 or claim 2, which is isolated.~~

~~43. The compound according to any one of claims 1 to 3, wherein the compound is characterized by the X-ray powder diffraction pattern (Cu radiation, $\lambda = 1.54059 \text{ \AA}$) comprising a peaks at 3.54, 12.51, 14.65, 20.37, 23.02 and 19.16 ($2\theta \pm 0.1^\circ$).~~

~~5. The compound according to claim 4, further comprising a peak at 3.54 ($2\theta \pm 0.1^\circ$).~~

~~6. The compound according to claim 4 or claim 5, further comprising a peak at 12.51 ($2\theta \pm 0.1^\circ$).~~

~~7. The compound according to any one of claims 4 to 6, further comprising a peak at 19.16 ($2\theta \pm 0.1^\circ$).~~

~~84. A pharmaceutical composition comprising~~ crystalline ((R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol monohydrate~~the compound as in any one of the preceding claims in combination with a pharmaceutically acceptable carrier, diluent or excipient.~~

5. The compound according to claim 1 characterized by the X-ray powder diffraction pattern (Cu radiation, $\lambda = 1.54059 \text{ \AA}$) comprising peaks at 12.51, 14.65, 20.37, 23.02 and 19.16 ($2\theta \pm 0.1^\circ$).

5 6. The compound according to claim 1 characterized by the X-ray powder diffraction pattern (Cu radiation, $\lambda = 1.54059 \text{ \AA}$) comprising peaks at 12.51, 14.65, 23.02 and 19.16 ($2\theta \pm 0.1^\circ$).

10 7. The compound according to claim 2 characterized by the X-ray powder diffraction pattern (Cu radiation, $\lambda = 1.54059 \text{ \AA}$) comprising peaks at 3.54, 12.51, 14.65, 20.37, 23.02 and 19.16 ($2\theta \pm 0.1^\circ$).

15 8. The compound according to claim 2 characterized by the X-ray powder diffraction pattern (Cu radiation, $\lambda = 1.54059 \text{ \AA}$) comprising peaks at 12.51, 14.65, 20.37, 23.02 and 19.16 ($2\theta \pm 0.1^\circ$).

9. The compound according to claim 2 characterized by the X-ray powder diffraction pattern (Cu radiation, $\lambda = 1.54059 \text{ \AA}$) comprising peaks at 12.51, 14.65, 23.02 and 19.16 ($2\theta \pm 0.1^\circ$).